A 36-year-old woman with rheumatoid arthritis was admitted to our hospital for evaluation of newl... more A 36-year-old woman with rheumatoid arthritis was admitted to our hospital for evaluation of newly developed active systemic lupus erythematosus (SLE). After hospitalization, she showed progressive respiratory failure. Chest CT revealed exacerbation of interstitial pneumonia, showing acute development of air-space consolidation and ground-glass opacity in addition to intensified reticular shadows. Administration of high-dose corticosteroids and cyclosporine A resulted in recovery from respiratory failure, accompanied by obvious improvement in the chest radiographs and CT, as demonstrated by the disappearance of air-space consolidation and ground-glass opacity. Clinically, the exacerbation of her interstitial pneumonia was compatible with acute lupus pneumonitis, a rare complication with active SLE.
Gert Van Isterdael, Julie Van Duyse, and Kelly Lemeire for extensive training. We thank Clint De ... more Gert Van Isterdael, Julie Van Duyse, and Kelly Lemeire for extensive training. We thank Clint De Nolf for his expertise in analyzing public scRNASeq datasets. We are thankful to prof. David Ron for providing us with critical reagents. The SJ laboratory is supported by an ERC Consolidator Grant (DCRIDDLE819314), FWO program grants (G017521N and G063218N), and an EOS grant (G0G7318N). The BNL laboratory is supported by ERC Advanced Grant, a concerted research initiative grant (GOA) from Ghent University (01G02817), and an EOS research grant. During this work, EC was supported by a FWO personal fellowship (11Z5615N). ND is supported by personal fellowships from FWO (11Y8417N and 1258921N).
Certain proteases derived from house dust mites and plants are considered to trigger initiation o... more Certain proteases derived from house dust mites and plants are considered to trigger initiation of allergic airway inflammation by disrupting tight junctions between epithelial cells. It is known that inhalation of proteases such as house dust mite-derived Der p1 and/or papaya-derived papain caused airway eosinophilia in naïve mice and even in Rag-deficient mice that lack acquired immune cells such as T, B and NKT cells. In contrast, little is known regarding the possible involvement of proteases derived from Aspergillus species (fungal-associated proteases; FAP), which are ubiquitous saprophytic fungi in the environment, in the development of allergic airway eosinophilia. Here, we found that inhalation of FAP by naïve mice led to airway eosinophilia that was dependent on protease-activated receptor-2 (PAR2), but not TLR2 and TLR4. Those findings suggest that the protease activity of FAP, but not endotoxins in FAP, are important in the setting. In addition, development of that eosin...
The Pfizer‐BioNTech mRNA vaccine (BNT162b2) is an effective and well‐tolerated coronavirus diseas... more The Pfizer‐BioNTech mRNA vaccine (BNT162b2) is an effective and well‐tolerated coronavirus disease 2019 (COVID‐19) vaccine. However, rare adverse events have been reported. We report two cases of COVID‐19 mRNA vaccine‐related interstitial lung disease (ILD). A 67‐year‐old man and a 70‐year‐old man with underlying ILD presented to our hospital with a few days of fever and respiratory symptoms after receiving the BNT162b2 vaccine. Drug‐related pneumonitis due to the COVID‐19 mRNA vaccine was diagnosed. One case was diagnosed with lymphocytic alveolitis by bronchoalveolar lavage fluid and transbronchial lung cryobiopsy. Both patients were successfully treated with corticosteroids, and they attended outpatient clinics thereafter. Although the safety and efficacy of COVID‐19 vaccines have been established, further studies are needed to estimate long‐term data and reports of rare adverse reactions. We present the clinical course of two cases, review previously published case reports on COVID‐19 mRNA vaccine‐related ILD and discuss the relevant findings.
Introduction The prevalence of asthma, chronic obstructive pulmonary disease (COPD), and asthma-C... more Introduction The prevalence of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO) in patients with COVID-19 varies, as well as their risks of mortality. The present study aimed to assess the prevalence of asthma, COPD, and ACO as comorbidities, and to determine their risks of mortality in patients with COVID-19 using a systematic review and meta-analysis. Methods We systematically reviewed clinical studies that reported the comorbidities of asthma, COPD, and ACO in patients with COVID-19. We searched various databases including PubMed (from inception to 27 September 2021) for eligible studies written in English. A meta-analysis was performed using the random-effect model for measuring the prevalence of asthma, COPD, and ACO as comorbidities, and the mortality risk of asthma, COPD, and ACO in patients with COVID-19 was estimated. A stratified analysis was conducted according to country. Results One hundred one studies were eligible, and 1,229,434 pati...
Rationale: Bronchial thermoplasty (BT) is a bronchoscopic procedure that uses thermal energy to r... more Rationale: Bronchial thermoplasty (BT) is a bronchoscopic procedure that uses thermal energy to reduce airway smooth muscle and prevent chronic structural changes of asthmatic patients. BT was reported to improve asthma-related quality of life (QOL), suppress asthma exacerbation, and maintain pulmonary function for 5 years. However, the detailed changes in pulmonary function after BT are not well known. We aimed to clarify the changes in pulmonary function after BT treatment in severe asthma patients. Methods: We prospectively included uncontrolled severe asthma patients who underwent BT treatment at our institution since BT was available in 2015. We analyzed the measured parameters on pulmonary function test, pulmonary impedance, and the fraction of exhaled nitric oxide (FeNO) levels in these patients. All patients completed 3 times of BT treatment. Baseline functions were taken within one month prior to the first BT; post-treatment functions were examined one month after the third BT procedure. Results: There were 9 severely asthmatic patients, with mean age of 55.7 years and disease duration of 27.6 years, on GINA treatment Step 5; exacerbation rate was 6.7 times/year. QOL and asthma control scores improved in almost all of the patients. FEV 1 increased by 18%; the increases in the values of V75, V50, and MMF were 29%, 63%, and 46%, respectively. There were no changes in RV, FRC, and TLC. Respiratory resistance and respiratory reactance improved in 5 patients and 4 patients, respectively. A decrease of FeNO levels was observed in only 4 patients. Conclusion: BT improved symptoms, QOL, and pulmonary function, including V50, MMF, V75, and FEV 1 , in severely asthmatic patients.
CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE ... more CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE PATIENTS-COMPARISON BETWEEN PACO2, PVCO2, PTCCO2 AND ETCO2 SHOTA FUJIMOTO, MANABU SUZUKI, RITSU IBUSUKI, KENTARO TAMURA, SACHI MATSUBAYASHI, NAOKO NAGANO, YOSHIE TSUJIMOTO, TAMAKI KAKUWA, TOMOYUKI SUZUKI, KEITA SAKAMOTO, AYAKO SHIOZAWA, KONOMI KOBAYASHI, SHOTA YAMAMOTO, ERIKO MIYAWAKI, MASAO HASHIMOTO, SATORU ISHII, ERIKO MORINO, JIN TAKASAKI, GO NAKA, TERUHIKO SATO, MOTOYASU IIKURA, SHINYU IZUMI, YUICHIROU TAKEDA, HARUHITO SUGIYAMA Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE ... more CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE PATIENTS-COMPARISON BETWEEN PACO2, PVCO2, PTCCO2 AND ETCO2 SHOTA FUJIMOTO, MANABU SUZUKI, RITSU IBUSUKI, KENTARO TAMURA, SACHI MATSUBAYASHI, NAOKO NAGANO, YOSHIE TSUJIMOTO, TAMAKI KAKUWA, TOMOYUKI SUZUKI, KEITA SAKAMOTO, AYAKO SHIOZAWA, KONOMI KOBAYASHI, SHOTA YAMAMOTO, ERIKO MIYAWAKI, MASAO HASHIMOTO, SATORU ISHII, ERIKO MORINO, JIN TAKASAKI, GO NAKA, TERUHIKO SATO, MOTOYASU IIKURA, SHINYU IZUMI, YUICHIROU TAKEDA, HARUHITO SUGIYAMA Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
Diffuse pulmonary lymphangiomatosis (DPL) is a rare lymphatic disease that can cause diverse resp... more Diffuse pulmonary lymphangiomatosis (DPL) is a rare lymphatic disease that can cause diverse respiratory symptoms. A 22-year-old man, whose chest CT had shown an abnormality for years, presented with acute respiratory failure due to the abrupt onset of hemoptysis. The diagnosis of DPL was confirmed by surgical lung biopsy and lymphangiography. Histopathological investigation showed dilated vascular and lymphatic vessels. DPL can cause acute and life-threatening symptoms during its chronic clinical course. A coexisting anomaly in the venous system may be present in DPL patients with hemoptysis.
A 36-year-old woman with rheumatoid arthritis was admitted to our hospital for evaluation of newl... more A 36-year-old woman with rheumatoid arthritis was admitted to our hospital for evaluation of newly developed active systemic lupus erythematosus (SLE). After hospitalization, she showed progressive respiratory failure. Chest CT revealed exacerbation of interstitial pneumonia, showing acute development of air-space consolidation and ground-glass opacity in addition to intensified reticular shadows. Administration of high-dose corticosteroids and cyclosporine A resulted in recovery from respiratory failure, accompanied by obvious improvement in the chest radiographs and CT, as demonstrated by the disappearance of air-space consolidation and ground-glass opacity. Clinically, the exacerbation of her interstitial pneumonia was compatible with acute lupus pneumonitis, a rare complication with active SLE.
Gert Van Isterdael, Julie Van Duyse, and Kelly Lemeire for extensive training. We thank Clint De ... more Gert Van Isterdael, Julie Van Duyse, and Kelly Lemeire for extensive training. We thank Clint De Nolf for his expertise in analyzing public scRNASeq datasets. We are thankful to prof. David Ron for providing us with critical reagents. The SJ laboratory is supported by an ERC Consolidator Grant (DCRIDDLE819314), FWO program grants (G017521N and G063218N), and an EOS grant (G0G7318N). The BNL laboratory is supported by ERC Advanced Grant, a concerted research initiative grant (GOA) from Ghent University (01G02817), and an EOS research grant. During this work, EC was supported by a FWO personal fellowship (11Z5615N). ND is supported by personal fellowships from FWO (11Y8417N and 1258921N).
Certain proteases derived from house dust mites and plants are considered to trigger initiation o... more Certain proteases derived from house dust mites and plants are considered to trigger initiation of allergic airway inflammation by disrupting tight junctions between epithelial cells. It is known that inhalation of proteases such as house dust mite-derived Der p1 and/or papaya-derived papain caused airway eosinophilia in naïve mice and even in Rag-deficient mice that lack acquired immune cells such as T, B and NKT cells. In contrast, little is known regarding the possible involvement of proteases derived from Aspergillus species (fungal-associated proteases; FAP), which are ubiquitous saprophytic fungi in the environment, in the development of allergic airway eosinophilia. Here, we found that inhalation of FAP by naïve mice led to airway eosinophilia that was dependent on protease-activated receptor-2 (PAR2), but not TLR2 and TLR4. Those findings suggest that the protease activity of FAP, but not endotoxins in FAP, are important in the setting. In addition, development of that eosin...
The Pfizer‐BioNTech mRNA vaccine (BNT162b2) is an effective and well‐tolerated coronavirus diseas... more The Pfizer‐BioNTech mRNA vaccine (BNT162b2) is an effective and well‐tolerated coronavirus disease 2019 (COVID‐19) vaccine. However, rare adverse events have been reported. We report two cases of COVID‐19 mRNA vaccine‐related interstitial lung disease (ILD). A 67‐year‐old man and a 70‐year‐old man with underlying ILD presented to our hospital with a few days of fever and respiratory symptoms after receiving the BNT162b2 vaccine. Drug‐related pneumonitis due to the COVID‐19 mRNA vaccine was diagnosed. One case was diagnosed with lymphocytic alveolitis by bronchoalveolar lavage fluid and transbronchial lung cryobiopsy. Both patients were successfully treated with corticosteroids, and they attended outpatient clinics thereafter. Although the safety and efficacy of COVID‐19 vaccines have been established, further studies are needed to estimate long‐term data and reports of rare adverse reactions. We present the clinical course of two cases, review previously published case reports on COVID‐19 mRNA vaccine‐related ILD and discuss the relevant findings.
Introduction The prevalence of asthma, chronic obstructive pulmonary disease (COPD), and asthma-C... more Introduction The prevalence of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO) in patients with COVID-19 varies, as well as their risks of mortality. The present study aimed to assess the prevalence of asthma, COPD, and ACO as comorbidities, and to determine their risks of mortality in patients with COVID-19 using a systematic review and meta-analysis. Methods We systematically reviewed clinical studies that reported the comorbidities of asthma, COPD, and ACO in patients with COVID-19. We searched various databases including PubMed (from inception to 27 September 2021) for eligible studies written in English. A meta-analysis was performed using the random-effect model for measuring the prevalence of asthma, COPD, and ACO as comorbidities, and the mortality risk of asthma, COPD, and ACO in patients with COVID-19 was estimated. A stratified analysis was conducted according to country. Results One hundred one studies were eligible, and 1,229,434 pati...
Rationale: Bronchial thermoplasty (BT) is a bronchoscopic procedure that uses thermal energy to r... more Rationale: Bronchial thermoplasty (BT) is a bronchoscopic procedure that uses thermal energy to reduce airway smooth muscle and prevent chronic structural changes of asthmatic patients. BT was reported to improve asthma-related quality of life (QOL), suppress asthma exacerbation, and maintain pulmonary function for 5 years. However, the detailed changes in pulmonary function after BT are not well known. We aimed to clarify the changes in pulmonary function after BT treatment in severe asthma patients. Methods: We prospectively included uncontrolled severe asthma patients who underwent BT treatment at our institution since BT was available in 2015. We analyzed the measured parameters on pulmonary function test, pulmonary impedance, and the fraction of exhaled nitric oxide (FeNO) levels in these patients. All patients completed 3 times of BT treatment. Baseline functions were taken within one month prior to the first BT; post-treatment functions were examined one month after the third BT procedure. Results: There were 9 severely asthmatic patients, with mean age of 55.7 years and disease duration of 27.6 years, on GINA treatment Step 5; exacerbation rate was 6.7 times/year. QOL and asthma control scores improved in almost all of the patients. FEV 1 increased by 18%; the increases in the values of V75, V50, and MMF were 29%, 63%, and 46%, respectively. There were no changes in RV, FRC, and TLC. Respiratory resistance and respiratory reactance improved in 5 patients and 4 patients, respectively. A decrease of FeNO levels was observed in only 4 patients. Conclusion: BT improved symptoms, QOL, and pulmonary function, including V50, MMF, V75, and FEV 1 , in severely asthmatic patients.
CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE ... more CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE PATIENTS-COMPARISON BETWEEN PACO2, PVCO2, PTCCO2 AND ETCO2 SHOTA FUJIMOTO, MANABU SUZUKI, RITSU IBUSUKI, KENTARO TAMURA, SACHI MATSUBAYASHI, NAOKO NAGANO, YOSHIE TSUJIMOTO, TAMAKI KAKUWA, TOMOYUKI SUZUKI, KEITA SAKAMOTO, AYAKO SHIOZAWA, KONOMI KOBAYASHI, SHOTA YAMAMOTO, ERIKO MIYAWAKI, MASAO HASHIMOTO, SATORU ISHII, ERIKO MORINO, JIN TAKASAKI, GO NAKA, TERUHIKO SATO, MOTOYASU IIKURA, SHINYU IZUMI, YUICHIROU TAKEDA, HARUHITO SUGIYAMA Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE ... more CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE PATIENTS-COMPARISON BETWEEN PACO2, PVCO2, PTCCO2 AND ETCO2 SHOTA FUJIMOTO, MANABU SUZUKI, RITSU IBUSUKI, KENTARO TAMURA, SACHI MATSUBAYASHI, NAOKO NAGANO, YOSHIE TSUJIMOTO, TAMAKI KAKUWA, TOMOYUKI SUZUKI, KEITA SAKAMOTO, AYAKO SHIOZAWA, KONOMI KOBAYASHI, SHOTA YAMAMOTO, ERIKO MIYAWAKI, MASAO HASHIMOTO, SATORU ISHII, ERIKO MORINO, JIN TAKASAKI, GO NAKA, TERUHIKO SATO, MOTOYASU IIKURA, SHINYU IZUMI, YUICHIROU TAKEDA, HARUHITO SUGIYAMA Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
Diffuse pulmonary lymphangiomatosis (DPL) is a rare lymphatic disease that can cause diverse resp... more Diffuse pulmonary lymphangiomatosis (DPL) is a rare lymphatic disease that can cause diverse respiratory symptoms. A 22-year-old man, whose chest CT had shown an abnormality for years, presented with acute respiratory failure due to the abrupt onset of hemoptysis. The diagnosis of DPL was confirmed by surgical lung biopsy and lymphangiography. Histopathological investigation showed dilated vascular and lymphatic vessels. DPL can cause acute and life-threatening symptoms during its chronic clinical course. A coexisting anomaly in the venous system may be present in DPL patients with hemoptysis.
Uploads
Papers by Motoyasu Iikura